RBP7 functions as a tumor suppressor in HR + breast cancer by inhibiting the AKT/SREBP1 pathway and reducing fatty acid

Yue Yu, Zhihua Xu, Hao Zhou, Ruyan Xu, Jia Xu, Wenjun Liu, Yuxin Wu, Yue Qiu, Guangbo Zhang, Xue F. Huang, Yan ChenCancer 2024 · DOI

Abstract

RBP7 may function as a tumor suppressor in HR + BC by inhibiting the AKT/SREBP1 pathway and reducing fatty acid.

Introduction

Hormone receptor-positive (HR+) breast cancer accounts for approximately 70% of all breast cancer cases. While endocrine therapies are the standard of care, nearly 30% of patients eventually develop drug resistance, leading to recurrence. Metabolic reprogramming—the process by which cancer cells alter their metabolism to fuel rapid growth—is a key driver of this progression. This study investigates Cellular Retinol Binding Protein 7 (RBP7) as a potential tumor suppressor and prognostic marker in HR+ breast cancer, specifically focusing on its role in regulating lipid metabolism.

Methods

The researchers employed a multi-disciplinary approach to investigate RBP7:

  • Bioinformatics: Analysis of large-scale genomic data from TCGA (615 HR+ BC cases) and GTEx (459 normal samples) to correlate RBP7 expression with patient survival.
  • Experimental Models: In vitro functional assays (CCK-8, colony formation, wound-healing) and in vivo NCG mouse models using modified MCF7 cells.
  • Metabolic Profiling: Visualization of lipid droplets using Nile Red and Oil Red O staining, alongside quantitative free fatty acid (FFA) measurements.
  • Clinical Validation: Analysis of 151 local clinical samples via tissue microarray (TMA) from the First Affiliated Hospital of Soochow University.

Results

RBP7 as a Prognostic Marker

Bioinformatic and clinical analyses revealed that RBP7 expression is significantly lower in HR+ breast cancer tissues compared to normal breast tissues. High RBP7 expression was associated with a significant survival advantage: patients with high expression had a median survival of 10.6 years, compared to 9.1 years for those with low expression (Hazard Ratio = 0.472).

Differential expression and prognostic significance of RBP7 in HR+ breast cancer. Panels (e) and (f) illustrate the downregulation of RBP7 in tumor tissues. Panels (c) and (d) show forest plots for univariate and multivariate Cox regression.

Inhibition of the AKT/SREBP1 Pathway

The study identified that RBP7 acts as a metabolic gatekeeper by inhibiting the AKT/SREBP1 signaling axis. RBP7 suppresses the phosphorylation (activation) of AKT, which in turn inhibits SREBP1, a master transcription factor for lipid synthesis. This disruption leads to a measurable decrease in intracellular free fatty acids and lipid droplets, effectively starving the tumor cells of the lipids needed for membrane construction and energy. Furthermore, high levels of RBP7 were found to induce cell cycle arrest in the G0/G1 phase.

In Vivo Tumor Suppression

Animal models confirmed these findings, demonstrating that overexpressing RBP7 significantly reduced tumor volume and weight in NCG mice. Conversely, knocking down RBP7 accelerated tumor growth, reinforcing its role as a potent tumor suppressor.

Conclusion

RBP7 functions as a critical tumor suppressor in HR+ breast cancer by disrupting fatty acid metabolism via the AKT/SREBP1 pathway. These findings suggest that RBP7 could serve as a reliable prognostic biomarker and that targeting the RBP7-AKT-SREBP1 axis may offer a new therapeutic strategy for overcoming resistance in HR+ breast cancer. Future work will focus on the interplay between vitamin A metabolism and lipid synthesis, as well as developing methods to reactivate RBP7 expression in clinical settings.

Summary updated

Abstract

RBP7 may function as a tumor suppressor in HR + BC by inhibiting the AKT/SREBP1 pathway and reducing fatty acid.
BibTeX
@inproceedings{yu2024rbp,
  author = {Yue Yu and Zhihua Xu and Hao Zhou and Ruyan Xu and Jia Xu and Wenjun Liu and Yuxin Wu and Yue Qiu and Guangbo Zhang and Xue F. Huang and Yan Chen},
  title = {{RBP7 functions as a tumor suppressor in HR + breast cancer by inhibiting the AKT/SREBP1 pathway and reducing fatty acid}},
  booktitle = {Cancer},
  year = {2024},
  doi = {10.1186/s12935-024-03299-0},
}
Figure